When the coronavirus pandemic reached the U.S., the FDA reacted swiftly to come up with quick solutions. In a few weeks, emergency testing was already in place, and that was an opportunity to convert some of the machines to be used as ventilators. The pandemic has paved the way for some new changes and trends, and they are going to have a significant impact on the medical industry. Here are five medical trends we could see very soon:

Approval Time is Going to be Faster

As the FDA’s emergency testing initiative is likely to expire, a backlog in approving medical devices is expected to occur due to the effects of COVID-19 as the clinical trial activities have been slowed down. Moreover, several sponsors diverted funds from clinical testing due to a significant declines in medical device sales. Several sites were also giving leave to their research personnel, leading to a sharp drop in clinical trials.

The FDA still needs to keep emergency measures in place for a period to address the backlog of issues, and this could see approval times getting shorter in the long term.

Acceptance of Remote Monitoring

Remote clinical research techniques are some of the methods that the FDA is proposing. It is considered as the preferable method since it will limit most movements during clinical studies. The FDA is also allowing some of the devices that measure body temperature and heart rate to be used remotely in the monitoring of patients, and allowing the use of these devices enables healthcare workers to access information about the patient’s vital signs. This remote monitoring has also become more comfortable due to the emergence of new enabling technology.

Use of Telemedicine for Clinical Trial Participants

Conducting meetings and evaluations is one of the protocols that were set by the FDA. Telemedicine is soon coming to the forefront in leading medical and healthcare visits. During this pandemic, virtual tools, and telemedicine are the best alternative method for site visits.

Furthermore, adding more information by sponsors will demonstrate that telemedicine is the appropriate tool for conducting clinical research.

Change to the Patients’ Recruitment Strategies

The use of social media platforms in recruiting, engaging, and retaining clinical trial participants is another factor that the FDA is encouraging at this time. It will reduce onsite visits, thus paving the way for telemedicine and home visits. The strategy will reduce the risk of virus transmission. Besides, as remote monitoring is becoming more common, so could remote recruitment strategies.

Conducting More Remote Auditing

More sponsors are resorting to using remote auditing for their clinical trial sites and internal teams. The use of Trial Master File Reviews, a remote auditing tool, is already becoming common. It is both time and cost-saving than in-person reviews. Its use may also expand as device manufactures are realizing the value and benefit of remote trial reviews. The remotely run “Practice FDA Inspection” is also useful for study teams who cannot conduct in-person exercises.

As the months roll by, these trends are likely to gather more momentum, and industry players like Genprex Inc. (NASDAQ: GNPX) may already in advanced stages of incorporating these into their operational manuals.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more
• Interest in serotonergic psychedelics has dramatically increased within last decade
• Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc.

For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://nnw.fm/Yx7cC). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, appears to be a strong player in this developing new space.

“Scientific interest in serotonergic psychedelics . . . has dramatically increased within the last decade,” reported a recent article published by the American Society for Clinical Pharmacology and Therapeutics. “Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. . . .

“Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders,” the article, which was titled “Psychedelics as Medicines: An Emerging New Paradigm,” stated. “Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.”

This research has fueled growth in an industry based on psychedelic medication, a space where Cybin Corp. is emerging as a leader. The company is focused on furthering research and development of psilocybin-based medications through its wholly owned division, Serenity Life Sciences Inc. Psilocybin is a naturally occurring, non-habit-forming psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Cybin is committed to its mission of bringing “fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness and other health conditions.” With that mission in mind, Cybin also has a wholly owned division, called Journey Inc. that offers branded, proprietary products targeting mental wellness, the immune system, detoxification and overall general health and wellness.

Cybin is a mushroom life-sciences company advancing psychedelic and nutraceutical-based products. Cybin is launching psilocybin-based products in jurisdictions where the substance is not banned. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Pharmaceutical and health care services company Trxade Group has added new tools to its Bonum Health telemedicine platform that will help patients better inform themselves about their medical needs and their provider’s prescription recommendations
• Trxade Group operates a B2B pharmaceutical network that supports independent, neighborhood-based healthcare businesses with up-to-the-minute information on drug pricing
• The company also assists patients on a B2C basis through its subsidiaries that include Bonum Health’s telemedicine platform and Delivmeds’ pharmaceutical delivery service
• Trxade Group’s development of remote-access medical care during the past two years has proven timely in the face of restrictions on gatherings imposed during the novel coronavirus pandemic
• The company has been increasing its profile among investors with uplisting to the Nasdaq exchange and entry to the annual Russell’s Microcap Index

Growing health services provider Trxade Group (NASDAQ: MEDS) recently announced the expansion of its patient empowerment telehealth platform Bonum Health, which has added access to educational resources that can help better understand and direct their care management.

Trxade Group’s wholly owned mobile telehealth application will now link to the Merck Manual, a standard reference guide for physicians since 1899, according to the announcement. The company’s intent in further developing the Bonum Health app is to “encourage, enable, and empower patients” with information pertinent to their medical needs and provider’s drug recommendations.

Trxade Group has been undergoing significant portfolio development during recent months. The company’s mission is to help sustain independent, locally owned community pharmacies, and two years ago it boosted its own capacity to reach consumers directly when it acquired accredited Internet pharmaceutical Community Specialty Pharmacy, LLC (http://nnw.fm/8vwSD) and launched its consumer-based medication delivery app Delivmeds.com.

Trxade Group has since added its Bonum Health Hub telehealth service as a means for patients and providers to consult using mobile smart tech without a need for in-office visits. The secure, privacy-enabled technology has proven particularly timely during a year when a novel coronavirus reached pandemic-level global transmission and spurred health and government leaders to enact varied restrictions against group gatherings (http://nnw.fm/s3oUQ).

Trxade Group has this year seen its operation uplisted to the Nasdaq exchange as it has gathered funding, and last month it gained inclusion on this year’s Russell’s Microcap Index.

“This marks an exciting capital markets milestone in the growth and trajectory of our company as we continue to execute upon our growth strategy and raise awareness about the Company throughout the investment community,” Trxade Chairman and CEO Suren Ajjarapu stated in a news release at the time (http://nnw.fm/poK7m).

Trxade Group’s eBay-type B2B business model significantly lowers prescription drug costs, in part due to its emphasis on transparency. At the same time, the company’s revenues grew 94 percent during 2019 as a result of fee income for medications listed on the company’s web-based market platform (http://nnw.fm/bFr3J) and 11,400 independent pharmacies became new subscribers to the company’s platform for analyzing drug pricing on an up-to-the-minute basis.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• SRAX’s Sequire platform has grown to 75 publicly traded companies comprising 500,000+ active investors
• Sequire’s sales exceeded $2.5 million in Q2 2020 with additional $3 million expected to close in Q3
• Platform expansion set to follow definitive securities purchase agreement worth $13 million

With the importance of big data on the rise, it should come as no surprise that the finance industry is leveraging the use of data analytics to deliver increased transparency and improve communications with stakeholders on every level. SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, is leveraging this trend through Sequire, its innovative investor intelligence platform. Through the use of proprietary technology, Sequire unlocks big data analytics in powerful new ways that connect public companies with traders and long-term investors for communication and marketing campaigns.

Interactions between public companies, shareholders and future prospects are becoming increasingly complex, requiring innovative new strategies and creative solutions that only big data can provide. Sequire facilitates these communications through an online platform that allows public companies to monitor the activities of current investors, activate campaigns to engage existing shareholders and create marketing campaigns to attract new investment to the company.

Sequire’s success – despite the effect of COVID-19 lockdowns – has been significant so far in 2020, growing to 75 publicly-traded companies comprising 500,000+ active investors and traders with sales exceeding $2.5 million in Q2 2020 (http://nnw.fm/z6H1i). Expansion of the platform is imminent following recent news that the Company has entered into a definitive securities purchase agreement led by existing institutional investors for the purchase and sale of $13 million senior secured convertible debentures to fund a rapid expansion of the platform (http://nnw.fm/DVrg6).

“On Thursday, we announced a capital raise of $13 million, which we will use in part to fund the rapid expansion of Sequire,” said SRAX CEO and founder Christopher Miglino (http://nnw.fm/9fMKq). “Our clients have seen notable results from the platform and its related services. We’ve also seen a significant increase in the number of clients on the platform with Q2 sales hitting over $2.5 million and an additional $3 million in the pipeline, with a very high probability of closing in Q3.”

Along with Sequire, SRAX delivers a suite of specialized tools for other industries, delivering a digital competitive advantage for brands in the CPG, luxury goods and lifestyle verticals by integrating all aspects of the advertising experience into one platform. At a time when consumers are becoming increasingly aware of the value of their data, SRAX is more than several steps ahead with the company’s BIGtoken platform, comprising over 16 million users and providing them with compensation for their data while simultaneously creating reliable data sets that can be accessed by marketers for a fee.

New, innovative and creative uses of big data are increasingly being used to meet the demands of businesses looking to survive the current economic period. SRAX’s services meet this demand by giving clients the ability to target and access specific niche groups across 25,000 unique points of segmentation, providing a much-needed strategic edge to businesses of all types across almost every industry.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Federal prohibition has been a thorn in cannabis’ side for a long time. And even as tens of states move to legalize recreational and medical marijuana, it remains illegal at the federal level and this has held the industry back in many ways. For instance, state-legal cannabis cannot be considered ‘organic’, a title bestowed by the U.S. Department of Agriculture, even if the growers maintained the purported ‘organic’ standards while growing the crop. However, regulators in California, the largest legal cannabis market in the world, have unveiled proposed regulations for a program that would equal the federally bestowed ‘organic’ status.

Draft regulation for the OCal Program, a statewide certification program, was released in early May, with a public comment period open until July 7. According to the California Department of Food and Agriculture (“CDFA”), the program “will ensure that cannabis products bearing the OCal seal have been certified to consistent, uniform standards comparable to the National Organic Program.” The CDFA is required to have established the certification program for cannabis by January 1, 2021.

Growers who meet a certain set of rules, including proper use of the approved fertilizers and pesticides, will be able to apply the OCal seal to their crop, and brands looking to stand out will be able to charge their health-conscious customers a premium for OCal-certified products. California will join Washington state as the only two state-legal cannabis markets to consider an organic certification for marijuana products, and being the largest legal cannabis market in the nation, it could set a precedent for other states.

According to Kristin Nevedal, Chair and Founder of the International Cannabis Farmers Association, the state-based program will “probably instill more confidence.” Consumers are willing to spend a premium for products deemed ‘organic’, she says. “It’s recognizable, and the branding opportunities are readily apparent.” She adds that some cannabis companies have already been using the consumer appetite for organically grown cannabis and have started labeling their products ‘clean and green.’

Sarah Armstrong, policy chair for the Southern California Coalition, the largest cannabis trade association in the region, hopes the program will be cost-effective enough to be well-received by the industry. “Our hope is that the proposed program will be cost-effective enough that the cannabis industry can fully participate. Right now, testing expenses represent 10% of the cost of product production, resulting in an exceptionally pure product at no small expense. Hopefully, the Organics Program can work with cultivators to develop methods that ensure the program safeguards purity in a cost-effective manner.”

Experts say industry actors like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) could be hoping that many other states adopt similar quality standards so that the industry is lifted as a whole.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Digital data collection has played major roles in several aspects of our lives, reduced waste and removed room for human error. For example, airlines today transfer most of the data collection function to their customers, and we are willing (and even happy) to use our mobile devices to provide all the needed data, such as our seat preferences and other personal details. Banks have done the same, and so have other service providers. However, the field of clinical research has been slow in waking up to the immense benefits of digital data collection, and we cover some of the major considerations why this should no longer be the case.

How Mobile Devices Can Be Mobilized for Clinical Research

IT consumerization has made huge inroads into daily life, and it is now common for employees to use their own laptops and other mobile devices while doing company work. This trend can be tapped in the clinical trial space by allowing study participants to use their own devices to provide any needed information, rather than employing people to make journal entries or fill out survey forms.

Data protection, device synchronization and training of all participants is crucial if the digital data collection system is to work without hiccups and potentially-costly errors for the company engaged in important clinical research.

Why Digital Data Collection is Important During Clinical Studies

Lots of clinical trials involve thousands of participants, and gathering data from them manually, and then analyzing it manually, is very costly in terms of time, personnel and other resources.

Digitization cuts through all those challenges and significantly improves the accuracy of the data collected, and that means that researchers have a higher chance of getting answers to the issues they are investigating. For example, when patients provide data on the side effects they are experiencing while on an experimental drug, regulators and drug developers have a more accurate picture of the extent of any inherent shortcomings of the drug under development.

Not Everyone is a Digital Native

If you live in a busy metropolis, it may be hard for you to imagine that there are people who don’t have access to the internet or who don’t own a smartphone. Lack of connectivity and other such issues can be a real stumbling block in efforts to digitally collect data during clinical trials. Biomedical companies and other entities engaged in clinical trials therefore need to plan carefully and design mechanisms to adapt as best they can. For example, a data collection assistant can use their device to input data provided by older persons who don’t know how to use the internet.

All in all, digital data collection is the future of clinical trials, and companies engaged in research would do well to make the transition from manual systems to largely automated ones. Sector players like Genprex Inc. (NASDAQ: GNPX) have probably fine-tuned their digital data collection systems, and they are likely to move a lot faster than their counterparts who are still doing things the traditional manual way.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note
• Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back”
• Company closed transaction resulting in gross cash proceeds of approximately $2.2 million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Q1 2020 financial results and business highlights (http://ibn.fm/mFwpq) as well as receipt of cash proceeds of $2.2 million from exercise of warrants (http://ibn.fm/2n6x5).

“[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity,” said POAI CEO Dr. Carl Schwartz. “This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash runway to fund key clinical, regulatory and operational milestones for the next several quarters. In addition, we have significantly reduced the corporate structure of our Skyline Medical business to enable it to operate independently as we consider strategic alternatives for this business.”

According to Predictive Oncology’s report, for the quarter ended March 31, 2020, company revenues increased to $295,943 compared with $255,241 for the first quarter of 2019. Gross margins remained strong at 69% for the same period, compared with 71% in the 2019 period. Other Q1 highlights included the following:

• Continued initial study to sequence ovarian tumors and validate “reach-back” process; study is on schedule to be completed Q3 2020
• Signed LOI to acquire Quantitative Medicine, a biomedical analytics and computational biology company; closed early July Q3 2020
• Signed a term sheet to acquire both BioDtech and Soluble Therapeutics and its HSC(TM) Technology; closed in Q2 2020

In addition, POAI announced the closing of a previously announced transaction resulting in gross cash proceeds of approximately $2.2 million paid to the company, prior to deducting placement agent fees and offering expenses, through the exercise of certain existing warrants by several holders to purchase an aggregate of up to 1,396,826 shares of common stock at an exercise price of $1.575 per share. The shares of common stock issued upon exercise of the existing warrants are registered for resale pursuant to a registration statement on Form S-1.

In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock at an exercise price of $1.80 per share with an exercise period of five and one-half years from the issuing date. Predictive Oncology plans to use these funds for working capital and general corporate purposes.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Domestic REEs increasingly in demand for use in critical modern technologies, to decrease reliance on China
• UUUU announced earlier this year it is preparing to enter REE sector
• Energy Fuels’ fully licensed and constructed White Mesa Mill could be key player in producing country’s own REE supply

Increasingly in demand, rare earth elements (“REEs”) — and where they come from — have becoming a hot topic recently (http://nnw.fm/Ei1e1). Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest uranium producer in the United States and the leading conventional producer of vanadium, is in an ideal position to leverage that rising interest as the company prepares to enter the REE sector.

“[REEs are] an awfully hot topic right now for two reasons,” reports a recent “Forbes” article. “First, they’re increasingly in demand for critical modern technologies, ranging from computer hard drives and cell phones, to new-tech applications such as batteries for EVs and clean power storage, to critical defense items such as jet engines and lasers.

“Second,” the article continues, “supply is currently dominated by China (for mining alone, for example, China has 80% market share). China has cut off supplies to countries before, and just last year threatened to do so again, in retaliation against the trade war with America.”

The article, titled “For Near-Term U.S. Decoupling From China For Rare Earth Elements, Options Are Limited — But They’re Out There,” notes that a lot of people are focused on getting the United States in a more stable situation in terms of its supply of rare earth elements. Currently, the country relies heavily on China for its supply of the valuable elements.

In part, that desire has been sparked because of a recent warning Chinese President Xi Jinping that he might ban exports of REEs to the U.S. And second, the current COVID-19 pandemic has caused many companies to take a closer look at ways to decrease their reliance on China for essential items, not just REEs, in their global supply chains.

Earlier this year, Energy Fuels announced its entry into the REE space. The company is confident that its fully licensed and constructed White Mesa Mill, which is the only uranium and vanadium mill in operation in the country today, could be a key player in re-establishing the country’s ability to produce its own supply of REEs.

UUUU chose to enter the REE industry after an intense, months-long review and testing period. The intense due diligence process included discussions with technical experts and the U.S. government, which is actively seeking a domestic source of REE minerals, which it uses for national defense. As part of this effort, President Donald J. Trump issued a series of five presidential determinations declaring domestic REE production essential to national defense.

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (“ISR”) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today with a licensed capacity of more than 8 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• SRAX’s investor intelligence platform Sequire announces that Q2 2020 sales exceeded $2.5 million
• The platform has seen customer numbers swell to over 75 publicly listed companies, rising from 59 at start of year
• SRAX also announced its raise of $13 million through the sale of convertible debentures, equity warrants
• While also settling an outstanding secured term loan, proceeds from raise will be used to fuel Sequire’s rapid expansion plans

SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, announced that its investor intelligence platform, Sequire, has shown significant growth in the second quarter with sales exceeding $2.5 million (http://nnw.fm/ku3L4). Launched in its rebranded format during SRAX’s first quarter earnings announcement, Sequire has witnessed a sharp increase in customer interest in recent months, growing its client base to over 75 publicly traded companies in the US and Canada, with an aggregate of over 500,000 unique shareholders. The platform, which assists its clients in tracking and interacting with their shareholders, has rapidly become an essential digital tool for equity issuers seeking to broaden their shareholders’ registers during a largely unprecedented time in global markets.

SRAX also seized the opportunity to announce that it had raised $13 million through the sale of convertible debentures and equity warrants (http://nnw.fm/j6F7i), with the proceeds of the capital-raising exercise to be used to fund Sequire’s rapid growth. With client numbers growing by a remarkable 27% over the first six months of the year, the investor intelligence platform has seen its ability to better understand which types of investors are willing to buy different stocks become increasingly defined, thereby enabling Sequire to better serve its clients.

“On Thursday, we announced a capital raise of $13M, which we will use in part to fund the rapid expansion of Sequire,” said SRAX CEO and founder Christopher Miglino. “Our clients have seen notable results from the platform and its related services. We’ve also seen a significant increase in the number of clients on the platform with Q2 sales hitting over $2.5M and an additional $3M in the pipeline, with a very high probability of closing in Q3.”

Sequire has launched a number of new initiatives over the past few weeks so as to broaden its overall service offering to its corporate customers. In addition to its revolutionary ‘Stocks for Ads’ initiative (http://nnw.fm/HlJy1), which enables companies to subscribe for Sequire’s services and pay for media campaigns in exchange for stock, thus allowing them to conserve their cash reserves at an economically tumultuous time – the company has also recently introduced its Virtual Roadshow feature (http://nnw.fm/etyC7).

With companies unable to carry out their traditional investor relations agendas, digital exchanges with investors have increasingly become a priority for corporate management teams. The Virtual Roadshow feature allows companies to host video and audio meetings with both new investors and existing shareholders, while also allowing them to track their meeting attendees’ investments following the event. With investors progressively resorting to digital means to research and interact with new investment opportunities, Sequire and its diverse portfolio of services appear to be in greater demand than ever before.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

According to forecasts, the demand within the self-injection devices market is anticipated to grow a great deal in the years to come. This increase can be attributed to a number of factors as the discussion below explores.

Transferring Responsibility to Individuals

Over the years, there has been a growing consensus among experts and researchers that individuals (patients) need to play a bigger role in managing the different health conditions that they are afflicted with. In this regard, innovation efforts have gone towards developing a variety of products that put patients in the driver’s seat, and those products include self-injection devices. This shift is fueling the growth of the self-injection device industry.

The Growing Incidence of Diabetes

As the world’s population becomes more sedentary and switches to a diet that is high in processed carbs, the number of people suffering from diabetes, especially Type 2 diabetes, is exploding. It is not sustainable for a patient to go to hospital each time they need a shot of insulin, so self-injection device makers have devoted energy towards coming up with a variety of products to make it possible for patients to administer these shots while at home or at their workplaces. The population of diabetics alone has done a lot to boost the self-injection devices industry.

Strides in Cardiovascular Research

A lot of patients suffer from chronic conditions that affect the lungs, heart and liver. The latest research in the cardiovascular field has brought to market several liquid injectables which can help patients to have a better quality of life despite suffering from a chronic heart, liver or lung disease. Many of these remedies can be administered using self-injection devices, and this category of patients is contributing towards the growing demand for these devices.

A Spike in Pediatric Diabetes Cases

It’s worth mentioning here that the rising cases of diabetes among children is a major factor worthy of mention beyond lumping them together with the adult population. When a kid develops diabetes, that child is likely to depend on insulin injections for the rest of their life, and the advances in the treatment of this disease mean that we are looking at decades of this individual needing self-injection devices. As any pharmaceutical company will tell you, the repeated use of a treatment modality for years drives market growth, and kids with diabetes are exerting an influence in the growth of the self-injection devices market.

As societies transform, new healthcare challenges are emerging and the existing remedies may not be able to cope. These new realities could explain why players in the biomedical field, such as Genprex Inc. (NASDAQ: GNPX), are working round the clock to develop new technologies that respond to the evolving challenges of managing contemporary diseases.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Rare diseases have brought a more significant impact on the lives of several people more than AIDS and cancer combined, and statistics show that more than 450 million people are suffering from rare diseases worldwide. These rare diseases have escalated due to lack of education, shortage of improved technologies and infrastructure, which has made the diagnosis of these diseases so challenging. However, the good news is that steps are being taken to improve the diagnosis and treatment of rare diseases worldwide.

The Focus Should Be Changed from North America and Europe to the World

For the last 25 years since rare diseases emerged, little has been done to diagnose rare diseases. Focus has been on North America and Europe, thereby neglecting other countries. According to current data, 160,000-180,000 rare disease patients identified yearly came from Arabic countries and, at the same time, had autosomal recessive diseases. This scenario is attributed to the social norms that see a more significant frequency of same family marriages. Additionally, the family size in Arabic countries is also more significant than that of the two continents. Looking at the problem globally will therefore help to provide more diagnostics and treatment options.

Diagnosing Rare Disease Is a Big Challenge

The genetic makeup of different ethnicities is one major factor that should be taken into consideration when diagnosing rare diseases. For example, “a mutation in a Mongolian population might not have any functional consequence but the same mutation might have a big consequence and cause a disease in Caucasian populations.” This implies that thorough interpretation and analysis of medical information is essential to enable proper diagnosis. Sequencing a genome is not challenging; the difficulty lies in the accurate interpretation of the available information. Adequate handling of data is critical to avoid the misdiagnosis of patients.

Data Collection and Analysis Should be More Efficient

The collection of data from various ethnicities for the diagnosis of thousands of patients with the same disease should be coordinated globally. Furthermore, combining genetic testing with metabolomics and proteomics has interpreted data as accurate as possible. The multi-omics approach can give the medical community a better understanding of whether a given mutation may cause functional consequence on a metabolite level. To make the diagnostic process easy, it is important to come up with a system that permits doctors to simplify the sample collection process.

Global Awareness for Rare Disease on Rare Disease Day

Rare Disease Days have been organized since the founding of CENTOGENE by its founder Rolf and his team. On February 29 this year, the first global event was held in three cities around the world in Berlin, Mexico City, and Lahore. Rare Disease Day is always used by CENTOGENE to raise awareness and share information on rare diseases with doctors, scientists’ organizations, patients, and the general public.

The Future of Rare Diseases Lies on the Heart of Innovation

The rare disease space is experiencing a lot of innovation from pharmaceutical companies, and innovations like CRISPR and RNA silencing technology are changing the rare disease landscape. However, the high cost of these innovative drugs is an enormous burden on health care systems globally. These high costs need to be brought down, and the challenge of diagnosis and treatment of rare diseases will be a thing of the past. Entities like Predictive Oncology (NASDAQ: POAI) have clearly taken this challenge seriously and are doing their part to make diagnostics more reliable and affordable.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: With safety, security and personal protection more tenuous than ever, groundbreaking technology sets sector pioneers as clear industry leaders.

A global pandemic stoked by national protests and riots has created a world where fear and uncertainty run rampant. Enforcing national, state and local directives as well as providing security and protection for essential services such as hospitals and community municipalities has become increasingly important — and increasingly dangerous. Companies operating in the security industry recognize the growing demand for change and are eager to provide solutions. A global pioneer in the development of autonomous security capabilities, Knightscope, Inc. (Profile) looks to disrupt the $500 billion security industry with its patented technology that combines self-driving technology, robotics and artificial intelligence. Knightscope’s Autonomous Security Robots (“ASR”) provide 24/7/365 security and have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools, and corporations.

Wrap Technologies Inc. (NASDAQ: WRTC) is seeing an increased demand from U.S. law enforcement agencies for its exclusive BolaWrap(R), which enables police officers to safely and humanely restrain resisting subjects from a distance without inflicting pain. Axon Enterprise Inc. (NASDAQ: AAXN) has launched a mobile app for body cameras that features remote livestreaming and critical real-time alerts. ShotSpotter Inc. (NASDAQ: SSTI) reports that since the city of Miami adopted its unique ShotSpotter program in 2014, the city’s homicide rate has plummeted by 35% and gunshot incidents as an activity have been reduced by about 50%. And Tesla Inc. (NASDAQ: TSLA), a strong player in the autonomous, self-driving vehicle sector, says a significant update of its Autopilot driver-assist software will be released in the next two to four months.

• Knightscope, Inc. chosen by IBN to spotlight in inaugural Stock2Me podcast.
• Knightscope ASRs are designed to deliver on two priorities: providing a physical deterrent and gathering data to provide unprecedented situational awareness
• Company inprocess of raising up to $50 million in growth capital as it prepares for a potential public listing. Reg A+ offering to close on July 20, 2020 here.

First-Ever Podcast Features Groundbreaking Company

With security and safety at the forefront of today’s news across the country and even around the world, it’s no wonder that Investor Brand Network (“IBN”) chose a groundbreaking security technology company such as Knightscope, Inc. (Profile)  to spotlight in its inaugural Stock2Me podcast. Designed to be an invaluable source for the latest news and updates on market trends and movers in high-profile industry sectors, Stock2Me Podcast keeps its listeners in the loop by providing in-depth information about the inner workings of the ever-evolving North American markets.

The podcast’s first episode features an insightful interview between podcast host Stuart Smith and Knightscope Inc.’s chairman and CEO William Santana Li. Knightscope offers a unique combination of self-driving technology, robotics and artificial intelligence, explained Li during the podcast.

“The math problem we’re trying to solve is, there’s a million security guards across the U.S. There’s another million Iaw-enforcement professionals,” he said. “They actually need to operate 24/7. At any point in time, only about 500,000 humans are trying to secure 328 million people across 50 states. That math doesn’t work.”

Knightscope security robots are fully autonomous and designed to do basically two things, Li explained: provide a physical deterrent and gather data.

“What does that mean?” he asked. “Well, let’s say you’re driving down the highway, and you see a patrol car on the side. What is your immediate reaction? To pump the brakes. Very similarly, if you’re trying to do something nefarious and it’s 4 o’ clock in the morning and you pull into a hospital parking lot and there’s a five-foot-tall, 400-pound machine roaming around on its own — it’s fully autonomous, there’s no one remote controlling it — the strobe light is going and it says security on it and you have no idea what it does, you’re probably basically going to go and steal the car down the street and not there. And that’s what our clients have been experiencing across the country.”

At the same time, Li explained, the security robots gather as much data information from the environment as possible. “The machine [does] the . . .  monotonous and computational heavy work that no human could possibly do, and then . . . humans do the strategic decision making and enforcement work.”

Federal Purchase to Pave Way

Knightscope customers include malls, corporate campuses, manufacturing plants, logistics facilities, hospitals, law enforcement agencies, schools, cities, casinos, and residential and commercial properties, including 10 Fortune 1000 companies to date. Most recently, the company announced that it had received its first federal purchase order awarded through a General Services Administration (“GSA”) contract.

According to the announcement, the company has a one-year agreement, with the potential of renewing for up to five years total service time, to deploy an autonomous security robot (“ASR”) at an undisclosed location in Texas. Knightscope is optimistic that this contract will pave the way for additional deployments at the more than 170-plus locations managed by the same agency, and that other federal agencies may sign up for ASRs when they see the performance of the initial ASR in Texas.

Determined to Deliver on Mission

With more than 10,000 investors and over $40 million raised since the company began in 2013, Knightscope has firmly established its position as an industry leader in the public safety and security sector. But the company is determined to deliver on its mission to make the United States the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Consequently, the company is currently in the process of raising up to $50 million in growth capital as it prepares for a possible public listing. Shares are only available through Knightscope’s managing broker-dealer StartEngine, and the company will close its current round of Regulation A+ Investment Offering on July 20, 2020.

“The global security market is projected to expand at over 10% per year and reach over $165 billion by 2025,” StartEngine reports. “As public safety becomes more top of mind, Knightscope believes it is uniquely situated at the cross section of multiple key elements of the security market, like video analytics, which was valued at $1.6 billion in its own right.”

Safest Country in the World

While the Reg A+ offering is important, Li notes that the company’s “end goal and aspiration is to see if we can make the United States of America the safest country in the world. A public listing or an IPO or however you want to do it is not the end goal of the company. It is basically a financing, and that’s it. That’s not the mission of the company.”

“I think long term, you know, my personal aspiration is to build a $30 billion company that kind of looks like a defense contractor,” Li continued. “But instead of focusing on the Department of Defense, we would be focused on the Department of Justice, Homeland Security, the 19,000 law enforcement agencies and the 8,000 private security firms.”

Li concluded his Stock2Me podcast interview by noting that “people are starting to realize that, ‘oh, wow, remote monitoring is actually going to become the norm.’ This would be a very unique way to better secure the places you visit, the places you work, study and play,” he said. “I think for the last seven-plus years, we’ve been pretty much screaming at the top of our lungs that we need to reinvent, reimagine, reinvigorate public safety. I’m glad that finally the entire nation is focused on a fundamental issue. I don’t believe the founders of our country ever expected us to build a society where going to work and going to school or just being in our own community comes with the risk of being shot or killed. We need to provide new tools and a new way to think about Public Safety, and Knightscope is at the forefront of that discussion.”

Providing Much-Needed Answers

The security industry is clearly seeking solutions. Savvy companies are stepping up to provide much-needed, innovative answers.

Wrap Technologies Inc. (NASDAQ: WRTC) recently announced that more than 100 agencies had requested BolaWrap demonstrations or training just last month, with an additional 36 agencies applying for grant assistance since the June 4 debut of the company’s Grant Assistance Program. “Agencies have been reevaluating their use of force methods and tools during encounters with subjects who need to be detained,” said Wrap Technologies COO Mike Rothans, who noted that the company’s “remote restraint device is the only tool on an officer’s belt designed to restrain a noncompliant subject without inflicting pain.”

A global leader in connected public safety technologies, Axon Enterprise Inc. (NASDAQ: AAXN) has created a new app that delivers advanced situational awareness for support teams and helps make officers and communities safer. Axon said the industry’s first real-time mobile application allows law enforcement to use a mobile device to remotely view livestreamed Axon Body 3 camera or Axon Air drone footage. The Axon Aware app is bundled with and available at no additional cost for the company’s current OSP7+ subscription plan customers, as well as a la carte customers who have purchased Aware/Aware+ or Axon Air.

ShotSpotter (NASDAQ: SSTI) provides acoustic gunshot detection and precision-policing solutions to help law enforcement officials and security personnel prevent and reduce gun violence and make cities, campuses and facilities safer. The company’s flagship product, ShotSpotter Flex(TM), is the leading gunshot detection, location and forensic analysis system, and is trusted by more than 100 cities. In addition, the company’s ShotSpotter Missions(TM) uses artificial intelligence-driven analysis to help strategically plan patrol missions and tactics for maximum crime deterrence.

Finally, Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk announced on Twitter about the company’s rewritten version of Autopilot. The rewrite is expected to bring a host of new functionality. With Tesla building its most affordable car yet, Tesla continues to make products accessible and affordable to more and more people, ultimately accelerating the advent of clean transport and clean energy production. “Electric cars, batteries, and renewable energy generation and storage already exist independently, but when combined, they become even more powerful — that’s the future we want,” the company states.

The traditional practices of the security industry have remained virtually the same for years. Today’s society, however, is demanding change, as the safety and protection of every individual is becoming a top priority.

For more information, please visit Knightscope, Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.